Gastrointestinal Pancreatitis

References:

1. NCCN (National Comprehensive Cancer Network) V.1.2023. Accessed at: https://www.nccn.org/professionals/physician_gls/pdf/immunotherapy.pdf. Last accessed: 1-5-2023
2. Schneider J, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, et al. Management of immunerelated adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update. Journal of clinical oncology. 2023;39:4073-4126
3. Haanen, Obeid M, Spain L, Carbonnel F, Wang Y, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up . Annals of Oncology. 2022;33(12):1217-38
4. Ahmer JR, Abu-Sbeih H, Ascierto PA, Brufsky J, Cappelli LC, Cortazar FB, et al. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events. Journal for immunotherapy of cancer. 2021;9(6).
5. Egyptian drug authority KEYTRUDA® leaflet approval date: 23/05/2023.